الفهرس 
GROSS ANATOMY OF THE UTERUSOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
Leiomyomas, also known as fibroids or myomas, are the most common gynecologic neoplasm, occurring in 20%–30% of women of reproduc¬tive age. Symptoms attributable to leiomyomas can generally be classified into three distinct catego¬ries: abnormal uterine bleeding, pelvic pressure and pain, and reproductive dysfunction. Leiomyomas are one of the most common indications for women to have surgical intervention such as myomectomy or even hysterectomy.
Uterine Artery Embolization (UAE) for fibroid tumors is an effective minimally invasive treatment for leiomyomas and it can allow women to avoid hysterectomy in 80% of cases. The procedure has been rapidly accepted by the public and has gained acceptance from gynecologists around the world. Through the diligent efforts of researchers across the world, it has gained level 1 evidence from randomized trials that demonstrate the efficacy and safety of this procedure.
The choice of the best embolic agent is crucial in order to maintain the clinical success of the procedure and preserve the public and the gyneacologists trust in it. An increasing number of embolic agents currently are available; polyvinyl alcohol (PVA) and gelatine sponge are the embolic agents with the widest body of experience but increasingly newer, calibrated particles have been developed. Newer agents include: tris-acryl gelatin microspheres (TAGM) “Embosphere”, spherical polyvinyl alcohol (sPVA) “Contour SE”, Acrylamido PVA microspheres “BeadBlock” and Polyzene F–coated Hydrogel Microspheres “Embozene”.